Arrhythmias & electrophysiology
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis
Authors' conclusion
Among GLP-1 RAs and co-agonists, subcutaneous semaglutide is highlighted as the most effective intervention for reducing the risk of AF. Further studies focusing on arrhythmic outcomes are needed to confirm these findings.
Study context
- Population
- Patients with diabetes or obesity receiving GLP-1 RAs or co-agonists
- Participants
- 155,989 patients94 randomized controlled trials (RCTs)
- Comparison
- 12 GLP-1 RAs and co-agonists
- Outcome
- AF incidence
Methodological detailsrandomized controlled trials
- Randomized controlled trials
Pooled result
As reported in the abstract
Relative risk (95% CI)
Subcutaneous semaglutide vs placebo
0.82(0.68–0.99)
Subcutaneous semaglutide vs tirzepatide
0.57(0.37–0.88)
Further pooled results
| Outcome | Subcutaneous semaglutide | Tirzepatide | Dulaglutide |
|---|---|---|---|
| AF ranking (p-score, 0 worst to 1 best) | p-score 0.7885 | p-score 0.1830 | p-score 0.1750 |
Atrioventricular blocks
- Lixisenatide was associated with a decreased risk in atrioventricular blocks
Original publication
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis. Heart Rhythm. Published 26 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →